Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NMSS funds Adeona Pharma Trimesta clinical trial
Earlier, the company has received $5m grant from the NMSS in partnership with the NMSS’s Southern California chapter, with support from the National Institutes of Health, and $860,440
Earlier, the company has received $5m grant from the NMSS in partnership with the NMSS’s Southern California chapter, with support from the National Institutes of Health, and $860,440
Teduglutide is a novel, recombinant analogue of human glucagon-like peptide 2, a protein involved in the rehabilitation of the intestinal lining. Nycomed said the MAA for Teduglutide was
Almac claims FLT provides an antibody free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library. BioFocus has launched an
ADX71149 has been discovered under the collaboration between Addex and Ortho-McNeil-Janssen Pharmaceuticals. As per the terms of the agreement, Addex is entitled to receive up to EUR112m in
Lucentis, a vascular endothelial growth factor (VEGF) inhibitor, was first approved by the US Food and Drug Administration for the treatment of neovascular (wet) age-related macular degeneration (AMD)
The new subsidiary will be engaged on marketing and selling Astellas‘ global products like Omnic and OmnicOCAS as a tretamnet for functional symptoms of benign prostatic hyperplasia. Additionally,
In a pivotal randomized, double-blind Phase 3 study, the drug has shown improvement in overall survival based on results. In the trial, the median overall survival was 10
Xyzal, an antihistamine, is a prescription medication indicated for the symptoms of year round allergies, as well as a treatment for chronic hives and rashes of unknown cause
The company has posted loss from operations of $7.03m, compared to $14.15m for the comparable period in 2009. For the full year ended 31 December 2010, the company
As the primary objective of the trial, Versartis will assess the safety and tolerability of a single subcutaneous dose of VRS-317 in the trial. The company expects to